SPDR Gold Trust vs Vaxcyte Inc. Common Stock — how do they compare? SPDR Gold Trust trades at $380.86 (market cap $141.50B), while Vaxcyte Inc. Common Stock trades at $67.1 (market cap $10.63B). The key difference: SPDR Gold Trust is far larger — about 13.3× Vaxcyte Inc. Common Stock's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 75 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| GLD | PCVX | |
|---|---|---|
Market Cap | $141.50B | $10.63B |
Volume | 5,707,251 | 1,525,205 |
52-Week High | $495.90 | $73.82 |
52-Week Low | $362.32 | $40.32 |
Typical Hold Time | 75 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $9.26B |
Signals from Pluang's Aura AI — not financial advice
GLD is trading at $380.57, down 0.29% with a bearish technical signal showing 17 sell indicators versus 1 buy. The stock faces pressure from rising Treasury yields and Federal Reserve rate expectations, with support levels at $371-$374 and resistance at $377-$380. Recent news highlights gold's struggle against macroeconomic headwinds despite some safe-haven demand.
The outlook remains cautious with technical indicators signaling bearish momentum and fundamental data unavailable. Key risks include persistent high yields and dollar strength, though some analysts see tactical buying opportunities if prices approach $4,000 support. Wall Street sentiment is mixed amid ongoing rate uncertainty.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →